|
Intrahepatic Cholestasis
|
0.200 |
Biomarker
|
disease |
RGD |
Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis.
|
19002567 |
2009 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Renal and hepatic transporter expression in type 2 diabetic rats.
|
19356064 |
2008 |
|
Kidney Failure
|
0.200 |
Biomarker
|
disease |
RGD |
Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats.
|
21167265 |
2011 |
|
Chronic kidney disease stage 5
|
0.200 |
Biomarker
|
disease |
RGD |
Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy.
|
12110012 |
2002 |
|
Chronic kidney disease stage 5
|
0.200 |
Biomarker
|
disease |
RGD |
Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
|
23280877 |
2013 |
|
Acute kidney injury
|
0.200 |
Biomarker
|
disease |
RGD |
Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats.
|
18612803 |
2008 |
|
Chronic Kidney Diseases
|
0.120 |
Biomarker
|
group |
BEFREE |
Further clinical studies are warranted with a broader range of OCT2 substrates to determine whether CKD may differentially affect tubular secretion of drugs especially in patients with advanced CKD.
|
28483424 |
2017 |
|
Diabetes Mellitus
|
0.110 |
Biomarker
|
group |
BEFREE |
We investigated the influence of diabetes mellitus (DM), glycemic control with insulin, cimetidine (Oct2 inhibitor) and metformin (Oct2 substrate) on the kinetic disposition of GAB in rats.
|
29551575 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible associations of the variants in genes encoding organic cationic transporters-solute carrier family 22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1 (SLC47A1) with response to metformin in type 2 diabetes.
|
22882994 |
2013 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
OCT-2 immunostaining was primarily restricted in normal lymphoid tissue to B cells, and was absent from most T-cell neoplasms.
|
12598320 |
2003 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Exemplarily, gene-specific analyses of DNA methylation, mRNA and protein expression demonstrate lack of expression of the clinically important drug transporter OCT2 (encoded by SLC22A2) in cell lines due to hypermethylation compared to tumors or metastases.
|
27435027 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Using a randomized crossover design and continuous variables such as change in hearing threshold and biomarkers of acute renal injury as short-term endpoints, it was determined that pantoprazole, an organic cation transporter 2 inhibitor, did not ameliorate cisplatin-associated nephrotoxicity or ototoxicity.Cystatin C is a robust method to estimate glomerular filtration rate in patients with cancer.
|
29445029 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC.
|
27440728 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
|
22223530 |
2012 |
|
Hodgkin Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.
|
11154228 |
2001 |
|
Hodgkin Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
To check the genomic status of PU.1, BOB1, and OCT2 in HL, we performed metaphase fluorescence in situ hybridization (FISH) analysis of 10 HL cases using locus-specific bacterial artificial chromosome clones.
|
15796964 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2.
|
20141429 |
2010 |
|
B-Cell Lymphomas
|
0.040 |
Biomarker
|
group |
BEFREE |
J chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL; are particularly useful in highlighting LP cells; and, with rare exception, are of greater utility than OCT-2 and BOB.1 in differentiating CHL from NLPHL and other large B-cell lymphomas.
|
28851661 |
2017 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC.
|
27440728 |
2016 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
|
22223530 |
2012 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Using a randomized crossover design and continuous variables such as change in hearing threshold and biomarkers of acute renal injury as short-term endpoints, it was determined that pantoprazole, an organic cation transporter 2 inhibitor, did not ameliorate cisplatin-associated nephrotoxicity or ototoxicity.Cystatin C is a robust method to estimate glomerular filtration rate in patients with cancer.
|
29445029 |
2018 |
|
Classical Hodgkin's Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical studies revealed that the large atypical cells were CD30 (+), CD15 (weakly +), CD20 (-), CD45 (-), Pax5 (weakly +), BOB.1 (-), and Oct2 (-), indicating the coexistence of SMZL with cHL.
|
18486899 |
2008 |
|
Adult Classical Hodgkin Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical studies revealed that the large atypical cells were CD30 (+), CD15 (weakly +), CD20 (-), CD45 (-), Pax5 (weakly +), BOB.1 (-), and Oct2 (-), indicating the coexistence of SMZL with cHL.
|
18486899 |
2008 |
|
Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Previous studies have shown that loss of the human organic cation transporter OCT2 is the main factor contributing to oxaliplatin resistance in RCC, and that DNA hypermethylation and histone methylation play important roles in the transcriptional repression of <i>OCT2</i> in RCC.
|
31088315 |
2019 |
|
Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Overall, this study indicated that miR-489-3p and miR-630 function as oncotherapy-obstructing microRNAs by directly targeting OCT2 in RCC.
|
31649850 |
2019 |